Farshbafnadi Melina, Ghannadzadeh Kermani Pour Rad, Sattarzadeh Badkoubeh Roya, Geraiely Babak, Mehrpooya Maryam, Larti Farnoosh
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Department of Cardiology, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Heliyon. 2024 Oct 11;10(20):e39074. doi: 10.1016/j.heliyon.2024.e39074. eCollection 2024 Oct 30.
End-stage renal disease (ESRD) is a progressive chronic condition that is strongly associated with cardiovascular mortality. ESRD patients usually benefit significantly from kidney transplantation. Pulmonary hypertension (PH) is a common finding in ESRD patients that adversely affects their survival. It has also been associated with adverse increased mortality and morbidity following kidney transplantation. However, PH has also been thought to improve following kidney transplantation. The exact underlying pathophysiology of PH in ESRD patients is unknown. However, it has been believed to be multifactorial, involving endothelial dysfunction, volume overload, and arteriovenous fistula. Management of PH in kidney transplant candidates and ESRD patients is remarkably understudied. Several treatment options are available for the treatment of PH. However, studies conducted on treating PH in ESRD patients are scarce. There is an increased need for studies on ESRD patients with PH.
终末期肾病(ESRD)是一种进行性慢性疾病,与心血管死亡率密切相关。ESRD患者通常从肾移植中受益匪浅。肺动脉高压(PH)在ESRD患者中很常见,会对其生存产生不利影响。它还与肾移植后死亡率和发病率的增加有关。然而,也有人认为肾移植后PH会有所改善。ESRD患者PH的确切潜在病理生理学尚不清楚。然而,人们认为它是多因素的,涉及内皮功能障碍、容量超负荷和动静脉瘘。对肾移植候选者和ESRD患者中PH的管理研究明显不足。有几种治疗方案可用于治疗PH。然而,针对ESRD患者治疗PH的研究很少。对患有PH的ESRD患者的研究需求日益增加。